New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia With Gary Lyman, MD, MPH, and Maura Abbott, PhD, AOCNP®, CPNP
Keira Smith
Expert Analysis
Oncology Data Advisor™ · New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia Chemotherapy-induced neutropenia (CIN) is a potentially life-threatening toxicity of chemotherapy that has been recognized as a major risk factor for the development of infections in patients with cancer (NCCN, 2021). The severity and du...
Prioritizing Life After Testicular Cancer With Katie Murray, DO
Keira Smith
Expert Analysis
For patients with testicular cancer, planning is necessary to ensure that patients feel prepared regarding the implications of their disease in the years after they finish treatment. In this interview in honor of Testicular Cancer Awareness Month, Dr. Katie Murray, Assistant Professor at the University of Missouri Department of Surgery-Urology, shares advice for members of the cancer care team on how to counsel their patients on planning for life after testicular cancer.  
Exploring Recent Advances in Testicular Cancer Surgery and Access to Care With Andrew Winer, MD, FACS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Exploring Recent Advances in Testicular Cancer Surgery and Access to Care This interview in honor of Testicular Cancer Awareness Month features Dr. Andrew Winer, Chief of Urology at Kings County Hospital in New York. Dr. Winer discusses the ongoing research regarding new approaches for testicular cancer surgery...
Personalizing the Approach to Testicular Cancer Management With Aditya Bagrodia, MD, FACS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Personalizing the Approach to Testicular Cancer Management With Aditya Bagrodia, MD, FACS This interview in honor of Testicular Cancer Awareness Month features Dr. Aditya Bagrodia, an Associate Professor of Urology at the University of California, San Diego. Dr. Bagrodia explains the factors that should be cons...
Exploring Recent Advances in Testicular Cancer Surgery and Access to Care With Andrew Winer, MD, FACS
Keira Smith
Expert Analysis
This interview in honor of Testicular Cancer Awareness Month features Dr. Andrew Winer, Chief of Urology at Kings County Hospital in New York. Dr. Winer discusses the ongoing research regarding new approaches for testicular cancer surgery, strategies to address disparities in health care access for underserved populations, and the importance of taking a multidisciplinary approach to achieve the best possible outcomes for patients with testicular cancer.  
Considering Venous Thromboembolism Risk Factors and Prophylaxis in Multiple Myeloma With Rajshekhar Chakraborty, MD, and Rahul Banerjee, MD
Keira Smith
Special Episode
Oncology Data Advisor™ · Considering VTE Risk Factors and Prophylaxis in Myeloma: Rajshekhar Chakraborty and Rahul Banerjee In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial B...
Personalizing the Approach to Testicular Cancer Management With Aditya Bagrodia, MD, FACS
Keira Smith
Expert Analysis
This interview in honor of Testicular Cancer Awareness Month features Dr. Aditya Bagrodia, an Associate Professor of Urology at the University of California, San Diego. Dr. Bagrodia explains the factors that should be considered when selecting treatment options—including surgery, chemotherapy, radiation, or surveillance—for patients with testicular cancer, the future of recent advances such as cancer detection with microRNA, and the importance of taking a multidisciplinary approach to ensure the best possible outcomes for patients with this disease.  
Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer With Ticiana Leal, MD, and Beth Sandy, MSN, CRNP
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer An estimated 236,740 new cases of lung cancer are reported in the United States annually, and 130,180 people die of the disease. Approximately 84% of cases are classified as non–small cell lung cancer (NSCLC) (ACS, 2022). Th...
Can Diet and Nutrition Impact Multiple Myeloma Outcomes? Food for Thought From Urvi Shah, MD, and Rahul Banerjee, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Can Diet and Nutrition Impact Multiple Myeloma Outcomes? Urvi Shah and Rahul Banerjee In honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor editorial board, speaks with Dr. Urvi Shah...
The Groundbreaking Approval of Tebentafusp for Uveal Melanoma With Richard Carvajal, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · The Groundbreaking Approval of Tebentafusp for Uveal Melanoma With Richard Carvajal, MD Recently, the FDA granted approval to tebentafusp for the treatment of patients with human leukocyte antigen (HLA)-A*02:01–positive unresectable or metastatic uveal melanoma, marking the first agent to be approved for this r...
Can Digital Health Tools Improve Quality of Life in Multiple Myeloma? Insights from Neha Korde, MD, and Rahul Banerjee, MD
Keira Smith
Expert Analysis
In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Neha Korde of Memorial Sloan Kettering Cancer Center about the potential of digital health tools to improve quality of life for patients with multiple myeloma.  
Considering Venous Thromboembolism Risk Factors and Prophylaxis in Multiple Myeloma With Rajshekhar Chakraborty, MD, and Rahul Banerjee, MD
Keira Smith
Expert Analysis
In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Rajshekhar Chakraborty of Columbia University Irving Medical Center about risk factors for the development of venous thromboembolism (VTE) in patients with multiple myeloma and the considerations for thromboprophylaxis during their treatment.  
Can Diet and Nutrition Impact Multiple Myeloma Outcomes? Food for Thought From Urvi Shah, MD, and Rahul Banerjee, MD
Keira Smith
Expert Analysis
In honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor editorial board, speaks with Dr. Urvi Shah about the importance of ensuring proper diet and nutrition, as well as the impact of the microbiome, for patients with multiple myeloma.  
Advocating for Patients During Multiple Myeloma Clinical Trial Design and Post-Protocol: Manni Mohyuddin, MBBS, and Rahul Banerjee, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Advocating for Patients in Multiple Myeloma Clinical Trials: Manni Mohyuddin and Rahul Banerjee In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor editorial boar...
The Groundbreaking Approval of Tebentafusp for Uveal Melanoma With Richard Carvajal, MD
Keira Smith
Expert Analysis
Richard Carvajal, MD. Recently, the FDA granted approval to tebentafusp for the treatment of patients with human leukocyte antigen (HLA)-A*02:01–positive unresectable or metastatic uveal melanoma, marking the first agent to be approved for this rare ocular malignancy. In this interview, Dr. Richard Carvajal, Associate Professor of Medicine at Columbia University Irving Medical Center and editorial board member of Oncology Data Advisor, discusses the practice-changing significance of the approval of tebentafusp and delves further into future directions in the development of treatments for uveal melanoma.  
The Roles of Etiology and Biopsy in Hepatocellular Carcinoma With Augusto Villanueva, MD, PhD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · The Roles of Etiology and Biopsy in Hepatocellular Carcinoma With Augusto Villanueva, MD, PhD At the recent American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, Dr. Augusto Villanueva, an Associate Professor of Medicine at Mount Sinai Hospital, discussed the role of the four main etiologies of hepatocellular carcinoma (HCC) in the response that patients may experience to treatment with immune checkpoint inhibitors. In this interview, Dr. Villanueva delves further into the question of whether etiology should play a part in immune-based treatment selection, as well as the role of liquid biopsy for patients newly diagnosed with HCC.  
Advocating for Patients During Multiple Myeloma Clinical Trial Design and Post-Protocol: Manni Mohyuddin, MBBS, and Rahul Banerjee, MD
Keira Smith
Expert Analysis
In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor editorial board, speaks with Dr. Manni Mohyuddin about the importance of designing clinically relevant end points for clinical trials in multiple myeloma. 
The Roles of Etiology and Biopsy in Hepatocellular Carcinoma With Augusto Villanueva, MD, PhD
Keira Smith
Expert Analysis
Augusto Villanueva, MD, PhD. At the recent American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, Dr. Augusto Villanueva, an Associate Professor of Medicine at Mount Sinai Hospital, discussed the role of the four main etiologies of hepatocellular carcinoma (HCC) in the response that patients may experience to treatment with immune checkpoint inhibitors. In this interview, Dr. Villanueva delves further into the question of whether etiology should play a part in immune-based treatment selection, as well as the role of liquid biopsy for patients newly diagnosed with HCC. 
Rare Disease Day With Amy DeZern, MD, MHS: Making Progress in Myelodysplastic Syndromes
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Rare Disease Day With Amy DeZern, MD, MHS: Making Progress in Myelodysplastic Syndromes In honor of Rare Disease Day on February 28, Oncology Data Advisor spoke with Amy DeZern, MD, MHS, Director of the Bone Marrow Failure and Myelodysplastic Syndromes (MDS) Program at Johns Hopkins Medicine and member of the Aplastic Anemia and MDS International Foundation (AAMDSIF) medical advisory board. In this interview, Dr. DeZern explains the challenges of treating such a rare disease and shares some of recent promising updates in novel treatments for patients with MDS.  
Interpreting the CAR T Results of Tisagenlecleucel for Relapsed/Refractory Non-Hodgkin Lymphoma: Michael R. Bishop, MD
Elizabeth Heller, PhD
Expert Analysis
Michael Bishop, MD. In the phase 3 BELINDA trial, a team of researchers led by Dr. Michael Bishop, Director of Hematopoietic Stem Cell Transplantation at the University of Chicago Medicine, investigated tisagenlecleucel (tisa-cel), a chimeric antigen receptor (CAR) T-cell therapy, as second-line treatment for patients with relapsed/refractory aggressive non-Hodgkin lymphoma. The investigators found that tisa-cel did not improve event-free survival compared with the standard of care, which consisted of platinum-based chemotherapy followed by autologous stem cell transplant in responders. Dr. Bishop recently presented the results of the trial at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia. In this interview with Oncology Data Advisor, he explains how these results should be interpreted and their significance for the future of CAR T-cell therapy.  

Copyright © 2022 Oncology Data Advisor. All rights reserved.